CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter ...

From September 2024 to October 2025, there was a 26 percent reduction in infections in adult, pediatric, and neonatal ...

The Pitt season premiere, "7:00 a.m.," ignores clichés in favor of a gritty, realistic, and uncompromising take on the ...

CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases.

Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒‒ Expects ...

CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...

A new Indian study warns that the drug-resistant fungus Candida auris is spreading worldwide and becoming deadlier. Led by researchers from Vallabhbhai Patel Chest Institute with support from the ...

Up to 189 health conditions could potentially affect your ability to drive, with seven specific conditions that must be ...

The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year.

The article " Why CorMedix Could be the Biopharma Name to Watch Early in 2026 " first appeared on MarketBeat.

Edema develops when lymph does not return to the venous circulation at a rate equal to the rate of capillary filtration. Fetal sheep develop edema as well as an increased central venous pressure while ...

There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy.